头颈癌预测风险估计器用于确定放疗控制与治疗结局(HNC-PREDICTOR):头颈癌临床可用基于模型的风险分层的开发、国际多机构验证及网络实现
研究基于三个学术癌症中心4611例头颈癌放疗患者数据,分为训练队列(n=2241)、独立测试队列(n=786)及外部验证队列1(n=1087)和2(n=497),利用机器学习 pipeline 预测总生存(主要终点)及局部和区域肿瘤控制(次要终点),并可选加入影像特征。表现评分、AJCC第8版分期、包年数和年龄被确定为总生存预测因子,训练队列 c-index=0.72(95%CI 0.66-0.77),三个验证队列 c-index 分别为0.76(0.69-0.83)、0.73(0.68-0.77)和0.75(0.68-0.80)。模型将患者分为高、中、低死亡风险组,高风险组5年总生存率为17-46%,低风险组为92-98%;加入形态学影像特征后性能进一步提升(c-index=0.73 [0.64-0.81])。模型已整合至临床可用交互式网页界面。
要点
- 基于多机构大数据构建的模型可稳健预测头颈癌患者总生存并将患者分为高、中、低死亡风险组。
- 高风险组5年总生存率为17-46%,低风险组为92-98%。
- 模型已整合至临床可用交互式网页界面供使用。
核心结论
- 基于模型的稳健预测能够将头颈癌患者分为不同的高、中、低死亡风险组,可有效用于个性化放疗,例如肿瘤放疗剂量递增/递减。
研究设计与样本
- 研究纳入三个学术癌症中心的4611例头颈癌放疗患者,分为训练队列(n=2241)、独立测试队列(n=786)、外部验证队列1(n=1087)和外部验证队列2(n=497)。
- 考虑肿瘤和患者相关临床变量,采用机器学习 pipeline 预测总生存(主要终点)及局部和区域肿瘤控制(次要终点),并序贯考虑影像特征以可选改进模型。
主要发现
- 表现评分、AJCC第8版分期、包年数和年龄被确定为总生存预测因子。
- 训练队列 c-index=0.72(95%CI 0.66-0.77),三个验证队列 c-index 分别为0.76(0.69-0.83)、0.73(0.68-0.77)和0.75(0.68-0.80)。
- 高风险组5年总生存率为17-46%,低风险组为92-98%。
- 加入形态学影像特征后性能进一步提升(c-index=0.73 [0.64-0.81])。
关键数值与推荐
- 总生存预测因子包括表现评分、AJCC第8版分期、包年数和年龄。
- 训练队列 c-index=0.72(95%CI 0.66-0.77)。
- 验证队列 c-index 分别为0.76(0.69-0.83)、0.73(0.68-0.77)和0.75(0.68-0.80)。
- 高风险组5年总生存率为17-46%,低风险组为92-98%。
- 加入形态学影像特征后 c-index=0.73(95%CI 0.64-0.81)。
临床怎么用
- 模型已整合至临床可用交互式网页界面:https://uic-evl.github.io/hnc-predictor/。
- 基于模型的风险分层可用于个性化放疗,例如肿瘤放疗剂量递增/递减。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Personalised radiotherapy can improve treatment outcomes of patients with head and neck cancer (HNC), where currently a 'one-dose-fits-all' approach is the standard. The aim was to establish individualised outcome prediction based on multi-institutional international 'big-data' to facilitate risk-based stratification of patients with HNC. METHODS: The data of 4611 HNC radiotherapy patients from three academic cancer centres were split into four cohorts: a training (n = 2241), independent test (n = 786), and external validation cohorts 1 (n = 1087) and 2 (n = 497). Tumour- and patient-related clinical variables were considered in a machine learning pipeline to predict overall survival (primary end-point) and local and regional tumour control (secondary end-points); serially, imaging features were considered for optional model improvement. Finally, patients were stratified into high-, intermediate-, and low-risk groups. RESULTS: Performance score, AJCC8thstage, pack-years, and Age were identified as predictors for overall survival, demonstrating good performance in both the training cohort (c-index = 0.72 [95% CI, 0.66-0.77]) and in all three validation cohorts (c-indices: 0.76 [0.69-0.83], 0.73 [0.68-0.77], and 0.75 [0.68-0.80]). Excellent stratification of patients with HNC into high, intermediate, and low mortality risk was achieved; with 5-year overall survival rates of 17-46% for the high-risk group compared to 92-98% for the low-risk group. The addition of morphological image feature further improved the performance (c-index = 0.73 [0.64-0.81]). These models are integrated in a clinic-ready interactive web interface: https://uic-evl.github.io/hnc-predictor/ CONCLUSIONS: Robust model-based prediction was able to stratify patients with HNC in distinct high, intermediate, and low mortality risk groups. This can effectively be capitalised for personalised radiotherapy, e.g., for tumour radiation dose escalation/de-escalation.
引用
- van Dijk LV, Mohamed AS, Ahmed S, et al. Head and neck cancer predictive risk estimator to determine control and therapeutic outcomes of radiotherapy (HNC-PREDICTOR): development, international multi-institutional validation, and web implementation of clinic-ready model-based risk stratification for head and neck cancer. Eur J Cancer. 2022. PMID: 36442460. doi:10.1016/j.ejca.2022.10.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。